S

Surgalign Holdings Inc
F:RT2

Watchlist Manager
Surgalign Holdings Inc
F:RT2
Watchlist
Price: 3.03 EUR -2.73% Market Closed
Market Cap: €20.1m

EV/OCF

-0.3
Current
18%
More Expensive
vs 3-y median of -0.2

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-0.3
=
Enterprise Value
€9.7m
/
Operating Cash Flow
$-42m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-0.3
=
Enterprise Value
€9.7m
/
Operating Cash Flow
$-42m

Valuation Scenarios

Surgalign Holdings Inc is trading above its industry average

If EV/OCF returns to its Industry Average (18.7), the stock would be worth €-207.52 (6 949% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-6 949%
Maximum Upside
No Upside Scenarios
Average Downside
6 583%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple -0.3 €3.03
0%
Industry Average 18.7 €-207.52
-6 949%
Country Average 16.7 €-185.35
-6 217%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Surgalign Holdings Inc
F:RT2
20.1m EUR -0.3 -0.5
JP
Hoya Corp
TSE:7741
9.8T JPY 36.8 39.1
US
Medline Inc
NASDAQ:MDLN
62.6B USD 0 0
CH
Alcon AG
SIX:ALC
30.7B CHF 18.2 39.2
DK
Coloplast A/S
CSE:COLO B
97.7B DKK 17.5 25.3
US
Align Technology Inc
NASDAQ:ALGN
13.6B USD 21 33.1
UK
ConvaTec Group PLC
LSE:CTEC
4.7B GBP 16.3 35.6
CA
Bausch + Lomb Corp
NYSE:BLCO
6B USD 37.4 -16.5
JP
Asahi Intecc Co Ltd
TSE:7747
927.6B JPY 21.7 52.4
KR
HLB Inc
KOSDAQ:028300
8.3T KRW -89.9 -37.7
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.4B USD 14.5 23.2
P/E Multiple
Earnings Growth PEG
US
S
Surgalign Holdings Inc
F:RT2
Average P/E: 35.4
Negative Multiple: -0.5
N/A N/A
JP
Hoya Corp
TSE:7741
39.1
15%
2.6
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
CH
Alcon AG
SIX:ALC
39.2
32%
1.2
DK
Coloplast A/S
CSE:COLO B
25.3
21%
1.2
US
Align Technology Inc
NASDAQ:ALGN
33.1
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
35.6
41%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -16.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
52.4
40%
1.3
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -37.7 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
23.2
30%
0.8

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 9 518 companies
0th percentile
-0.3
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Surgalign Holdings Inc
Glance View

Market Cap
20.1m EUR
Industry
Health Care

Surgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. The company is headquartered in Deerfield, Illinois and currently employs 231 full-time employees. The company went IPO on 2000-08-10. The firm is focused on developing an augmented reality (AR) and artificial intelligence (AI) digital surgery platform called HOLO AI, which is an artificial intelligence technology being applied to surgery. The technology is designed to automatically segment and identify detailed patient spine anatomy, autonomously create a surgical plan for surgeon review, and then provide visual guidance with augmented reality to the surgeon in the surgical field. The company has a portfolio of spinal hardware implants, including solutions for fusion procedures in the lumbar, thoracic, and cervical spine, motion preservation solutions for the lumbar spine, and a minimally invasive surgical implant system for fusion of the sacroiliac joint. The company also has a biomaterials portfolio of advanced and traditional orthobiologics. The firm offers its products to hospitals, ambulatory surgery centers and healthcare providers in the United States.

RT2 Intrinsic Value
Not Available
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett